Semaglutide (GLP-1) Peptide

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) analog. GLP-1 peptide is an endogenous peptide hormone containing 30-31 amino acids. Ongoing research suggests that the primary implications of this compound are increased insulin production, reduced glycemic levels, and conservation of pancreatic beta cells by stimulating insulin gene transcription. Additionally, the compound appears to delay gastric emptying, leading to appetite suppression and reduced caloric intake. Semaglutide, as a GLP-1 receptor agonist, may potentially lower gastric motility and glucose, reduce appetite, and induce weight loss.⁽¹⁾ The peptide may exert its potential via various pathways, including:^(2)(3)(4)

• Possibly binding with the GLP-1 receptors in pancreatic tissues, promoting glucose-dependent insulin release.
• Possibly suppressing the release of glucagon and inhibiting the hepatic synthesis of glucose.
• Possibly via pancreatic beta cell functioning, improving the proinsulin-to-insulin ratio
• Possibly delaying gastric motility, interacting with hunger-regulating centers and reducing appetite.